Considering that the new FASN inhibitor TVB‐2640 is the first‐in‐class in clinical trials, the data provide a rationale for utilizing FASN inhibitors in the treatment of prostate cancer, especially those with Pten loss. Here, PTEN is linked to prostate cancer.